Exelixis, Inc. is an oncology-focused biotechnology company headquartered in Alameda, California. Founded in 1994, it specializes in the discovery, development, and commercialization of new medicines for difficult-to-treat cancers.
The company's flagship product is cabozantinib, marketed as CABOMETYX for advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ for progressive, metastatic medullary thyroid cancer. CABOMETYX and COMETRIQ inhibit multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. Exelixis also offers COTELLIC (cobimetinib), a MEK inhibitor used in combination for certain advanced melanomas.
With approximately 1,077 employees, Exelixis maintains a robust pipeline including small molecules like zanzalintinib and biotherapeutics such as antibody-drug conjugates. The company collaborates with partners including Ipsen, Takeda, Roche, and Bristol-Myers Squibb to advance its oncology programs. Traded on Nasdaq under EXEL, Exelixis continues to evolve as a multi-platform cancer therapeutics provider.
